ABL1 and leukemia: Moreover, ABL regulates cardiomyocyte growth and development (32), and its inhibition is directly linked to cardiotoxic events (33, 34) and immunosuppression (35) in patients with leukemia, which makes unwanted ABL inhibition a clinical liability.